INTEGRATED ASSESSMENT OF STATIN-ASSOCIATED MUSCLE DAMAGE PREDICTORS IN PATIENTS WITH ISCHEMIC HEART DISEASE
<p>Aim. To assess the risk factors of statin-associated muscle damage in patient with ischemic heart disease.<br />Material and methods. 258 patients with ischemic heart disease treated with statin were included into the study. Total plasma creatine kinase levels were measured and SLCO1B...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | http://www.rpcardio.ru/jour/article/view/33 |
| _version_ | 1797708569985941504 |
|---|---|
| author | V. I. Petrov O. N. Smuseva Yu. V. Solovkina |
| author_facet | V. I. Petrov O. N. Smuseva Yu. V. Solovkina |
| author_sort | V. I. Petrov |
| collection | DOAJ |
| description | <p>Aim. To assess the risk factors of statin-associated muscle damage in patient with ischemic heart disease.<br />Material and methods. 258 patients with ischemic heart disease treated with statin were included into the study. Total plasma creatine kinase levels were measured and SLCO1B1*5 genotyping was performed. Relationship between statin therapy and adverse events was evaluated by Naranjo algorithm.<br />Results. Patients with muscle symptoms received statins significantly longer (48.8 vs 11.9 months, р<0.0001) and in higher doses, than patients without muscle pain/weakness. There were not significant differences in creatine kinase levels between patients with and without muscle symptoms. Patients with SLCO1B1*5 genotype were revealed in both groups, but more often (58%) among patients with muscle symptoms. Patients with abnormal C allele having muscle symptoms received statins significantly longer, than these without muscle signs (54.7 vs 13.9 months, р=0.0028).<br />Conclusion. Association between occurrence of muscle symptoms and SLCO1B1*5 allele carriership, statin dose and therapy duration was revealed. Creatine kinase examination was not valuable for finding of statin-induced muscle damage.</p> |
| first_indexed | 2024-03-12T06:24:31Z |
| format | Article |
| id | doaj.art-fcf72c7041af4fd7aeb6dae0fdda48f4 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-03-12T06:24:31Z |
| publishDate | 2015-09-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-fcf72c7041af4fd7aeb6dae0fdda48f42023-09-03T02:03:11ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-019324725010.1234/1819-6446-2013-3-247-25033INTEGRATED ASSESSMENT OF STATIN-ASSOCIATED MUSCLE DAMAGE PREDICTORS IN PATIENTS WITH ISCHEMIC HEART DISEASEV. I. Petrov0O. N. Smuseva1Yu. V. Solovkina2Волгоградский государственный медицинский университет, ВолгоградВолгоградский государственный медицинский университет, ВолгоградВолгоградский государственный медицинский университет, Волгоград<p>Aim. To assess the risk factors of statin-associated muscle damage in patient with ischemic heart disease.<br />Material and methods. 258 patients with ischemic heart disease treated with statin were included into the study. Total plasma creatine kinase levels were measured and SLCO1B1*5 genotyping was performed. Relationship between statin therapy and adverse events was evaluated by Naranjo algorithm.<br />Results. Patients with muscle symptoms received statins significantly longer (48.8 vs 11.9 months, р<0.0001) and in higher doses, than patients without muscle pain/weakness. There were not significant differences in creatine kinase levels between patients with and without muscle symptoms. Patients with SLCO1B1*5 genotype were revealed in both groups, but more often (58%) among patients with muscle symptoms. Patients with abnormal C allele having muscle symptoms received statins significantly longer, than these without muscle signs (54.7 vs 13.9 months, р=0.0028).<br />Conclusion. Association between occurrence of muscle symptoms and SLCO1B1*5 allele carriership, statin dose and therapy duration was revealed. Creatine kinase examination was not valuable for finding of statin-induced muscle damage.</p>http://www.rpcardio.ru/jour/article/view/33статинынежелательная лекарственная реакциямиопатияSLCO1B1*5креатинкиназа |
| spellingShingle | V. I. Petrov O. N. Smuseva Yu. V. Solovkina INTEGRATED ASSESSMENT OF STATIN-ASSOCIATED MUSCLE DAMAGE PREDICTORS IN PATIENTS WITH ISCHEMIC HEART DISEASE Рациональная фармакотерапия в кардиологии статины нежелательная лекарственная реакция миопатия SLCO1B1*5 креатинкиназа |
| title | INTEGRATED ASSESSMENT OF STATIN-ASSOCIATED MUSCLE DAMAGE PREDICTORS IN PATIENTS WITH ISCHEMIC HEART DISEASE |
| title_full | INTEGRATED ASSESSMENT OF STATIN-ASSOCIATED MUSCLE DAMAGE PREDICTORS IN PATIENTS WITH ISCHEMIC HEART DISEASE |
| title_fullStr | INTEGRATED ASSESSMENT OF STATIN-ASSOCIATED MUSCLE DAMAGE PREDICTORS IN PATIENTS WITH ISCHEMIC HEART DISEASE |
| title_full_unstemmed | INTEGRATED ASSESSMENT OF STATIN-ASSOCIATED MUSCLE DAMAGE PREDICTORS IN PATIENTS WITH ISCHEMIC HEART DISEASE |
| title_short | INTEGRATED ASSESSMENT OF STATIN-ASSOCIATED MUSCLE DAMAGE PREDICTORS IN PATIENTS WITH ISCHEMIC HEART DISEASE |
| title_sort | integrated assessment of statin associated muscle damage predictors in patients with ischemic heart disease |
| topic | статины нежелательная лекарственная реакция миопатия SLCO1B1*5 креатинкиназа |
| url | http://www.rpcardio.ru/jour/article/view/33 |
| work_keys_str_mv | AT vipetrov integratedassessmentofstatinassociatedmuscledamagepredictorsinpatientswithischemicheartdisease AT onsmuseva integratedassessmentofstatinassociatedmuscledamagepredictorsinpatientswithischemicheartdisease AT yuvsolovkina integratedassessmentofstatinassociatedmuscledamagepredictorsinpatientswithischemicheartdisease |